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About one-third of the patients with ischemic stroke caused by an intracranial large vessel occlusion do not recover to 
functional independence, despite early and complete recana-
lization by endovascular treatment (EVT).1 Although EVT 
is successful in reopening large intracranial arteries, it does 
not always restore microvascular perfusion. This incomplete 
microvascular reperfusion, also described as the no-reflow 
phenomenon, has first been reported in animal studies.2–4 
One of the causes of microvascular obstruction is the forma-
tion of neutrophil extracellular traps, which are known to be 
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present in all thrombi of ischemic stroke patients irrespective 
of stroke cause.5 neutrophil extracellular traps are resistant to 
r-tPA (recombinant tissue-type plasminogen activator), but 
experimental studies show that unfractionated heparin is able 
to dissolve neutrophil extracellular traps at the microvascular 
level.6–9 The effect of unfractionated heparin on neutrophil ex-
tracellular traps in humans has not been evaluated. In the pre-
EVT era, no benefit of heparin use on outcome in ischemic 
stroke patients was seen, with a concomitant 1.2% increase in 
occurrence of symptomatic intracranial hemorrhage (sICH).10 
However, as the rate of successful recanalization is high in 
patients treated with EVT, heparin is now more capable of 
penetrating the downstream microvessels and targeting the 
no-reflow areas. That heparin may contribute to the treatment 
effect of EVT is not a new concept but originates from cardi-
ology practices: periprocedural heparin has been used since 
the first percutaneous coronary intervention performed in 
1977 and is standard practice since then.11 By contrast, heparin 
is not the standard anticoagulant in EVT for ischemic stroke, 
which might be related to the perceived risk of sICH. In a 
systematic literature review, we found that heparin use during 
EVT indeed seems to be associated with an increased risk of 
sICH, but this increase seems to be outweighed by a higher 
overall chance of a good functional outcome.12 The risk-bene-
fit ratio of periprocedural intravenous heparin in patients with 
ischemic stroke undergoing EVT is still unclear. The uncer-
tainty regarding this risk-benefit ratio is also reflected in the 
wide variation in the use of heparin in randomized trials that 
investigated the effect of EVT.13 We aimed to evaluate the use 
of intravenous heparin during EVT in Dutch stroke interven-
tion centers and to assess its efficacy and safety.
Methods
Study Design
We used data from the MR CLEAN Registry (Multicenter Randomized 
Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke), 
which is an ongoing, nationwide, multicenter, prospective, observa-
tional study, including all consecutive patients treated with EVT for 
ischemic stroke in the Netherlands. The complete methods and de-
scription of variables of the MR CLEAN Registry have been described 
elsewhere.14 For the present study, we selected patients who were reg-
istered between March 2014 and June 2016 and adhered to the follow-
ing criteria: age of ≥18 years; treatment in a center that participated 
in the MR CLEAN trial; presence of a proximal intracranial occlusion 
in the anterior circulation confirmed on noninvasive vascular imaging 
(intracranial carotid artery [internal carotid artery (terminus)], middle 
cerebral artery [M1/M2], anterior cerebral artery [A1/A2]); and groin 
puncture within 6.5 hours after symptom onset. The current observa-
tional study was guided by the STROBE statement (Strengthening the 
Reporting of Observational Studies in Epidemiology).15 Data cannot 
be made available, as no patient approval has been obtained for shar-
ing coded data. However, syntax files and output of statistical analyses 
in R will be made available on request.
Unfractionated Heparin Administration
Heparin administration was defined as any intravenous dose of 
unfractionated heparin administered during EVT. We explored the 
variability in doses of heparin used and percentages of patients 
treated with heparin within and between centers and over time. When 
information on heparin administration was missing, we assumed no 
heparin was administered to the patient. We performed 2 sensitivity 
analyses on this matter. First, we compared baseline characteristics of 
the group of patients whom we assumed not to have been treated with 
heparin to the patients explicitly registered as not treated with hep-
arin. Second, we performed a complete case analysis of the primary 
and secondary outcomes in patients explicitly registered as treated 
with heparin versus no heparin.
Outcome Measures
The primary outcome was functional outcome at 90 days (range 14 
days either way), assessed with the modified Rankin Scale (mRS), 
which is a 7-point ordinal scale ranging from 0 no symptoms to 6 
dead.16 Secondary outcomes were good functional outcome (mRS ≤2) 
at 90 days, successful recanalization rate (extended Thrombolysis in 
Cerebral Infarction grade ≥ 2B) assessed by an independent imaging 
core laboratory, occurrence of sICH, defined as patient neurological 
deterioration (decline of 4 points or more on the National Institutes of 
Health Stroke Scale) and a compatible hemorrhage seen on imaging 
assessed by an independent imaging core laboratory (according to the 
Heidelberg criteria), mortality at 90 days, progression of ischemic 
stroke (resulting in a decline of at least 4 points on the National 
Institutes of Health Stroke Scale), new ischemic stroke (imaging of 
new brain infarction with corresponding clinical neurological deficit), 
extracranial hemorrhage, and cardiac ischemia (myocardial ischemia 
confirmed by ECG and release of appropriate biomarkers).
Statistical Methods
Differences in baseline characteristics were analyzed for both cate-
gorical and dichotomous variables using χ2 statistics. Continuous 
data were assessed for normality both visually and by means of 
Kolmogorov-Smirnov testing. One-way ANOVA was used for par-
ametric and Kruskal-Wallis for nonparametric testing. A P value of 
<0.05 was considered significant in all applied tests. All baseline data 
and outcomes that are reported are crude and not imputed. Any mRS 
score assessed within 30 days of symptom onset was considered in-
valid and treated as missing. For the purpose of unbiased estimation 
of associations of outcome with baseline characteristics, we replaced 
missing outcome values when missing in <10% of the patients (eg, 
mRS) by values derived from multiple imputation.17 Multiple imputed 
data were used in the adjusted outcome analyses. We used multi-
level logistic and ordinal regression analyses to compare outcomes 
of patients treated with and without periprocedural intravenous hep-
arin, with center as random effect and relevant factors as fixed effects 
(ie, heparin use, age, sex, National Institutes of Health Stroke Scale at 
admission, prestroke mRS, antiplatelet use, direct oral anticoagulant 
use, coumarin use, previous stroke, diabetes mellitus, glucose level at 
baseline, international normalized ratio, baseline systolic blood pres-
sure, occlusion segment, Alberta Stroke Program Early CT Score at 
baseline, collateral grading, treatment with intravenous alteplase, an-
esthesia type, preinterventional extended Thrombolysis in Cerebral 
Infarction (eTICI) score, intraarterial thrombolysis, and onset-to-
reperfusion time). Effects are presented as (adjusted common) odds 
ratios (OR) with 95% CI. To account for possible confounding by 
indication, we also analyzed the effect of center preference to admin-
ister heparin, defined as percentage of patients treated with heparin in 
a center, on outcome. All statistical analyses were performed with R 
version 3.5.0 (R foundation for Statistical Computing, Vienna, Austria) 
with the packages: tableone, mice, Hmisc, ggplot, and ordinal.
Results
Patient Population
From the total cohort of 1627 patients, 1488 patients from 
16 centers were included and analyzed, of whom 398 (27%) 
received intravenous heparin (Figure 1). Among patients 
who received intravenous heparin, the median dose was 
5000 international units (IU), ranging from 1250 to 10 000 
IU (Figure I in the online-only Data Supplement). The per-
centage of patients within a center treated with intravenous 
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heparin ranged from 0% to 94% (Figure 2). Over the inves-
tigated time period, both the total proportion of patients re-
ceiving heparin and the proportion of patients receiving 
heparin per center remained stable (Figure II in the online-
only Data Supplement). Patients receiving heparin presented 
more often with a stroke in the left hemisphere (233/398 
[59%] versus 563/1090 [52%], P=0.03) and used coumarins 
less often (39/398 [10%] versus 151/1090 [14%], P=0.04; 
Table 1). Median time from emergency room admission at 
the intervention center to groin puncture (80 [51, 114] versus 
66 [38, 99] minutes, P<0.01) and time from symptom onset 
to reperfusion (282 [225, 338] versus 265 [214, 327] minutes, 
P=0.01) were both longer in the heparin group. In the hep-
arin group, patients received more often general anesthesia 
(215/398 [57%] versus 164/1090 [16%], P<0.01) and intra-
arterial thrombolytics (33/398 [8.3%] versus 20/1090 [1.8%], 
P<0.01) during EVT. The sensitivity analysis showed no sub-
stantial baseline differences between patients in whom no 
heparin use was explicitly registered and those with missing 
heparin administration in whom we assumed no heparin was 
administered (Table I in the online-only Data Supplement).
Outcome Measures
No statistically significant difference in median mRS was 
observed between patients who received heparin and those 
who did not (3 [2, 6] versus 3 [2, 6]; adjusted common OR 
1.17; 95% CI, 0.87–1.56; Figure 3). No statistically sig-
nificant associations were found between heparin use and 
good functional outcome (adjusted odds ratio [aOR], 1.29; 
95% CI, 0.88–1.88; Table 2), successful recanalization 
(aOR, 1.24; 95% CI, 0.89–1.79), sICH (aOR, 1.13; 95% CI, 
0.65–1.99), and mortality (aOR, 0.95; 95% CI, 0.66–1.38). 
There were also no statistically significant differences be-
tween both groups in any of the other secondary outcomes. 
Multiple imputation was performed for 125/1488 (<10%) of 
the main outcome. The complete case analysis showed sim-
ilar results (Table II in the online-only Data Supplement). 
The analyses of center preference to administer heparin 
showed that functional outcomes were better in centers 
with higher percentages of heparin administration (adjusted 
common OR, 1.07 per 10% increase in heparin use; 95% 
CI, 1.01–1.13 and for good functional outcome aOR 1.10 
per 10% increase in heparin; 95% CI, 1.02–1.18; Table 3). 
In the center preference analyses, there was no association 
between an increase in heparin use and successful recana-
lization (aOR, 1.07; 95% CI, 0.96–1.19), sICH (aOR, 0.98; 
95 % CI, 0.88–1.10), mortality (aOR, 0.95; 95% CI, 0.90–
1.01), and other secondary outcomes.
Figure 1. Flowchart. EVT indicates endovascular treatment; and MR 
CLEAN, Multicenter Randomized Clinical Trial of Endovascular Treatment 
of Acute Ischemic Stroke.
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Table 1. Baseline Demographics
Heparin (n=398) No Heparin (n=1090) P Value Missing
Common patient characteristics
  Age, y 68 (15) 69 (14) 0.68 0
  Male sex 206 (52%) 588 (54%) 0.49 0
  NIHSS at baseline 16 [12–20] 16 [11–20] 0.77 18/12
  Ischemia in left hemisphere 233 (59%) 563 (52%) 0.03 2/10
  Systolic blood pressure 149 (25) 150 (24) 0.81 20/22
  Diastolic blood pressure 81 (15) 82 (16) 0.56 19/28
  Treatment with IV alteplase 300 (76%) 861 (79%) 0.16 1/2
  INR 1.1 (0.4) 1.2 (0.4) 0.15 45/229
  Glucose level 7.4 (2.3) 7.5 (2.7) 0.52 27/145
  Trombocyte count 253 (90) 251 (93) 0.72 31/156
  Center volume (patients treated per center 
per year)
55 [48–58] 55 [38–79] 0.08 0
Medical history
  Previous stroke 66 (17%) 183 (17%) 0.98 2/7
  Atrial fibrillation 78 (20%) 249 (23%) 0.19 5/17
  Hypertension 185 (47%) 560 (52%) 0.10 5/14
  Diabetes mellitus 57 (14%) 198 (18%) 0.10 4/5
  Myocardial infarction 58 (15%) 169 (16%) 0.74 9/20
  Peripheral arterial disease 39 (10%) 96 (9.0%) 0.65 6/22
  Prestroke mRS >2 57 (15%) 114 (11%) 0.05 8/19
Medication use
  Antiplatelet 140 (35%) 353 (33%) 0.44 1/18
  DOAC 5 (1.3%) 32 (3.0%) 0.09 2/24
  Coumarin 39 (10%) 151 (14%) 0.04 0/11
  Blood pressure lowering medication 193 (49%) 568 (53%) 0.16 4/24
  Statin 143 (36%) 379 (36%) 0.90 3/28
Imaging
  Occluded segment   0.11 20/55
   Intracranial ICA 28 (7%) 54 (5%)   
   ICA-T 68 (18%) 245 (24%)   
   M1 226 (60%) 599 (58%)   
   M2 52 (14%) 123 (12%)   
   Other (eg, M3, ACA) 4 (1.1%) 14 (1.4%)   
  Reperfusion before intervention (eTICI)   0.34 27/111
   0 308 (83%) 799 (82%)   
   1 29 (7.8%) 56 (5.7%)   
   2A 7 (1.9%) 31 (3.2%)   
   2B 10 (2.7%) 28 (2.9%)   
   2C 3 (0.8%) 16 (1.6%)   
   3 14 (3.8%) 49 (5.0%)   
  ASPECTS 9 [7–10] 9 [7–10] 0.81 14/51
  ASPECTS ≤ 7 110 (29%) 324 (31%) 0.39 14/51
(Continued )
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Discussion
In the present observational study, substantial between-center 
variability was found in the percentage of patients treated with 
periprocedural intravenous heparin. We did not find a signifi-
cant effect of intravenous heparin use on functional outcome 
at the level of the individual patient. After mitigating potential 
unmeasured confounding by indication through analysis at the 
center level, we found a modest beneficial effect of heparin on 
functional outcome. Patients in centers that treat more patients 
with intravenous heparin had better functional outcomes, 
without increased sICH risk.
One of the first studies that introduced periprocedural use 
of intravenous heparin during EVT (by means of intraarte-
rial prourokinase) was the PROACT II trial (Prolyse in Acute 
Cerebral Thromboembolism II), in which a nonsignificant in-
crease in the risk of sICH was observed in the EVT arm com-
pared with the control arm, with an improvement in functional 
outcome (significant after stratification for stroke severity).18 
Patients in both arms received a total dose of 4000 IU of hep-
arin. Afterward several EVT trials implemented this as part 
of their protocol with doses ranging from 2000 to 5000 IU, 
whereas other trials did not.12,13 The uncertainty regarding 
the risk-benefit ratio and absence of recommendations in the 
guidelines explains the variability in periprocedural intrave-
nous heparin use in Dutch stroke intervention centers.19 In 
prior studies on periprocedural heparin use, the doses used 
are comparable to the median dose of 5000 IU of heparin in 
this study.13,20–22 Furthermore, we found that patients receiving 
heparin were less often on coumarins, which suggests that 
interventionists are more cautious to administer heparin in 
anticoagulated patients because of an allegedly higher sICH 
risk or the indication to administer heparin has already been 
treated by the coumarin. By contrast, we found that patients 
who received heparin were more likely to receive intraarte-
rial thrombolytics, which could probably be related to center 
policy. This might also be the case for general anesthesia, 
which was also more often used in the heparin group. The 
longer emergency room to groin puncture time in the heparin 
group may be explained by the fact that heparin was less often 
used in the 3 largest centers, in which the workflow may be 
  Collaterals   0.30 25/82
   Grade 0–absent collaterals 27 (7.2%) 70 (6.9%)   
   Grade 1–occluded area filling <50% 122 (33%) 339 (34%)   
   Grade 2–occluded area filling >50% but 
<100%
157 (42%) 378 (38%)   
   Grade 3–occluded area filling 100% 67 (18%) 221 (22%)   
Workflow (in minutes)
  Time from symptom onset to admission ER 
(intervention center)
133 [68–190] 135 [59–189] 0.73 20/53
  Time from admission ER to groin puncture 80 [51–114] 66 [38–99] <0.01 42/89
  Duration procedure 62 [40–87] 65 [40–95] 0.07 34/123
  Time from symptom onset to reperfusion 282 [225–338] 265 [214–327] 0.01 20/67
Procedural
  General anesthetic management 215 (57%) 164 (16%) <0.01 18/85
  Administration of intraarterial thrombolytic 33 (8.3%) 20 (1.8%) <0.01 0
Baseline variables with heparin vs no heparin. Continuous data are presented as mean (SD) for normal distributed data or as median [IQR] for 
skewed data. Categorical data are presented as n (%). ACA indicates anterior cerebral artery; ASPECTS, Alberta Stroke Program Early CT Score; 
DOAC, direct oral anticoagulant; ER, emergency room; eTICI, extended Thrombolysis in Cerebral Infarction including a 2C grade; ICA, internal 
carotid artery; ICA-T, ICA terminus; INR, international normalized ratio; IQR, interquartile range; IV, intravenous; mRS, modified Rankin Scale; and 
NIHSS, National Institutes of Health Stroke Scale.
Table 1. Continued
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Figure 3. Primary outcome on the modified 
Rankin Scale (mRS) at patient level.
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more optimized in comparison to the workflow of the other 
centers. The median duration of the procedure was, however, 
comparable between groups.
Two smaller post hoc analyses of randomized controlled 
trials (Multi MERCI [Multi Mechanical Embolus Removal 
in Cerebral Ischemia] and TREVO-II [Thrombectomy 
Revascularization of Large Vessel Occlusions in Acute Ischemic 
Stroke II]) investigating the effects of EVT also addressed the 
question of whether periprocedural heparin is beneficial.21,22 In 
both studies, periprocedural intravenous heparin use was asso-
ciated with higher rates of good functional outcomes. The ben-
eficial effect might be explained by the ability of intravenous 
heparin to restore incomplete microvascular reperfusion. The 
use of periprocedural heparin seems safe. In all our analyses, 
there was no statistically significant association between hep-
arin use and sICH or mortality. This is also in line with the find-
ings of the 2 aforementioned post hoc analyses of trials, which, 
however, did not adjust for risk factors for sICH. Finally, it is 
important to realize that periprocedural use of heparin is not 
novel in EVT practices as heparin has been used ever since 
the introduction of percutaneous coronary intervention in car-
diology.23 The rationale for heparin use during percutaneous 
coronary intervention is that the intervention is associated with 
factors that predispose to thrombosis (eg, stasis within the cor-
onary artery, stasis within the catheters, and exposure of blood 
coagulation factors to injured endothelium, catheters, and 
guidewires) and is, therefore, used as part of protocol care.11 
One reason why neuro-interventionists have not fully adopted 
heparin use in current practice might be the fear of sICH, which, 
based on our results, seems to be unjustified.
Given the variability in heparin administration among Dutch 
stroke intervention centers and the promising results regarding 
outcome, a randomized controlled trial is warranted to prospec-
tively evaluate adjunctive therapy and assess whether this is 
beneficial. In the ongoing trial MR CLEAN-MED (Multicenter 
Randomized Clinical Trial of Endovascular Treatment for Acute 
Ischemic Stroke in the Netherlands; the Effect of Periprocedural 
Medication: Heparin, Antiplatelet Agents, Both or Neither, 
ISRCTN76741621), patients are randomized to intravenous 
heparin and/or acetylsalicylic acid to investigate whether this 
will affect microvascular reperfusion and improve functional 
outcome. Our observational study showed a nonsignificant ab-
solute difference of 4% in good functional outcome (mRS 0–2) 
Table 2. Secondary Outcomes in Patients Treated With Heparin vs No Heparin
Heparin (n=398) No heparin (n=1090) P Value (c)OR, (95% CI) a(c)OR (95% CI)*
mRS ≤ 2 at 90 days 144 (41%) 373 (37%) 0.19 1.19 (0.93–1.53) 1.29 (0.88–1.88)
Reperfusion after intervention (eTICI ≥2B) 245 (62%) 604 (56%) 0.05 1.28 (1.01–1.62) 1.24 (0.89–1.71)
Symptomatic intracranial hemorrhage 25 (6.3%) 61 (5.6%) 0.71 1.13 (0.70–1.83) 1.13 (0.65–1.99)
Mortality at 90 days 105 (30%) 293 (29%) 0.78 1.05 (0.80–1.37) 0.95 (0.66–1.38)
Progression of stroke 40 (10%) 100 (9.2%) 0.68 1.11 (0.75–1.63) 0.89 (0.54–1.45)
New ischemic stroke 7 (1.8%) 17 (1.6%) 0.97 1.13 (0.47–2.75) 0.80 (0.26–2.46)†
Extracranial hemorrhage 13 (3.3%) 20 (1.8%) 0.14 1.81 (0.89–3.67) 1.66 (0.68–4.05)
Cardiac ischemia 5 (1.3%) 7 (0.6%) 0.40 1.97 (0.62–6.24) 2.05 (0.49–8.48)‡
Primary and secondary outcomes in patients treated with heparin vs. no heparin. Categorical data are presented as numbers (%). a(c)OR indicates adjusted 
(common) odds ratio; ASPECTS, Alberta Stroke Program Early CT Score; (c)OR, (common) odds ratio; eTICI, extended Thrombolysis in Cerebral Infarction; INR, 
international normalized ratio; mRS, modified Rankin Scale; and NIHSS, National Institutes of Health Stroke Scale.
*Variables in the model: (fixed effects) heparin use, age, sex, NIHSS at admission, prestroke mRS, intravenous alteplase, preinterventional eTICI score, 
antiplatelet use, direct oral anticoagulant use, coumarin use, previous stroke, diabetes mellitus, intraarterial thrombolysis, glucose at baseline, systolic blood 
pressure, anesthesia type, occlusion segment, ASPECTS at baseline, INR, onset to reperfusion, collateral grading, time per month (random effect) center.
†Direct oral anticoagulant use not in model due to lack of convergence.
‡Intraarterial thrombolysis not in model due to lack of convergence.
Table 3. Primary and Secondary Outcomes Associated With Percentage 
Heparin Use Per Center (Per 10% Heparin Increase)
a(c)OR, (95% CI; per 10% 
Heparin Increase)*
Primary outcome
  mRS at 90 days 1.07 (1.01–1.13)
Secondary outcomes
  mRS ≤ 2 at 90 days 1.10 (1.02–1.18)
  Reperfusion after intervention (eTICI ≥ 2B) 1.07 (0.96–1.19)
  Symptomatic intracranial hemorrhage 0.98 (0.88–1.10)
  Mortality at 90 days 0.95 (0.90–1.01)†
  Progression of stroke 1.00 (0.89–1.13)
  New ischemic stroke 1.10 (0.84–1.44)‡
  Extracranial hemorrhage 1.08 (0.90–1.29)
  Cardiac ischemia 1.13 (0.82–1.55)†
Primary and secondary outcomes associated with 10% increase in 
percentage of patients treated with heparin at center level. a(c)OR indicates 
adjusted (common) odds ratio; ASPECTS, Alberta Stroke Program Early CT 
Score; eTICI, extended Thrombolysis in Cerebral Infarction; INR, international 
normalized ratio; mRS, modified Rankin Scale; and NIHSS, National Institutes 
of Health Stroke Scale.
*Variables in the model: (fixed effects) percentage heparin use per 
10%, age, sex, NIHSS at admission, prestroke mRS, intravenous alteplase, 
preinterventional eTICI score, antiplatelet use, direct oral anticoagulant use, 
coumarin use, previous stroke, diabetes mellitus, intraarterial thrombolysis, 
glucose at baseline, systolic blood pressure, anesthesia type, occlusion 
segment, ASPECTS at baseline, INR, onset to reperfusion, collateral grading, 
time per month (random effect) center.
†Intraarterial thrombolysis not in model because of lack of convergence.
‡Direct oral anticoagulant use not in model because of lack of convergence.
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in favor of heparin. This supports the sample size calculation 
of MR CLEAN-MED, which is powered to detect an absolute 
difference in good functional outcome of 5%.
Limitations
Because of the observational design of our study, confound-
ing by indication could have influenced the results. For ex-
ample, patient-related factors that are associated with the 
outcome could have influenced the treating physician’s deci-
sion whether or not to administer heparin. For this reason, we 
adjusted for relevant prognostic factors that were likely to be 
associated with the administration of heparin. Furthermore, 
we performed an additional analysis in which we incorpo-
rated center preference to administer heparin to reduce the 
risk of possible unmeasured confounding by indication. In 
the latter analysis, confounding by indication at the interven-
tionist level diminishes as the analysis at center level is less 
likely to suffer from this type of confounding (not decision or 
indication dependent). Also, this analysis takes into account 
specific center-related factors not included in the model—
residual confounding—which could have influenced the phy-
sician’s choice to administer heparin. However, even in this 
center preference analysis, some residual confounding might 
be present. Possible examples of residual confounding are that 
centers using heparin more frequently could have been better 
equipped or that interventionists administering heparin have 
more experience. Unfortunately, we could not adjust for this. 
Furthermore, as the distribution of heparin use among centers 
varied widely, we considered it interesting to explore if center 
preference is actually the preference of the specific center or 
rather the preference of the specific interventionist within the 
center. However, because some interventionists work at dif-
ferent sites and as part of an intervention team with changing 
staff, it was not feasible to perform this more in-depth explo-
ration. Another limitation regarding this study is that activated 
clotting times were not measured, leaving the question unan-
swered if activated clotting times were adequately influenced 
by the treatment.
Conclusions
Substantial between-center variability exists in intravenous 
heparin use during EVT procedures in patients with ischemic 
stroke, but treatment is safe. Patients treated in centers that 
treat more patients with intravenous heparin have better func-
tional outcomes. A randomized trial is warranted to further 
study the effects of this treatment.
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